Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • ShortsalgSe hvilke børsnoterede selskaber der har offentliggjorte korte positioner
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Cereno Scientific

0,14 SEK-40,04 %17.11, 17.13
Mindre end 1K følgere

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Shortsalg
Investorernes syn
Sammenligne
-40,04 %
-96,15 %
-97,17 %
-97,47 %
-98,05 %
-98,04 %
-96,92 %
-97,43 %
-97,74 %

Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.

Læs mere
Markedsværdi
44,04 mio. SEK
Aktieomsætning
11,58 mio. SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper

Finanskalender
15.12
2026

Ekstraordinær generalforsamling '26

3.2
2027

Årsrapport '26

Selskabsmeddelelse17.11.2026, 17.11

Cereno Scientific announces resignation of Chairperson of the Board at his own request

Cereno Scientific
Selskabsmeddelelse16.11.2026, 22.35

Cereno Scientific announces resignation of Board member at own request

Cereno Scientific
Eksterne analyser16.11.2026, 09.54

Cereno Scientific: More runway, more opportunity - Edison

Cereno Scientific has outlined a comprehensive financing package, comprising a proposed SEK400m rights issue and restructuring of its existing SEK175m Fenja debt, marking an important step towards addressing the funding overhang on its clinical programmes...

Cereno Scientific

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse13.11.2026, 08.26

Cereno Scientific provides clarification regarding the trading suspension

Cereno Scientific
Selskabsmeddelelse13.11.2026, 08.00

Cereno Scientific gives notice to attend Extraordinary General Meeting

Cereno Scientific
Selskabsmeddelelse12.11.2026, 17.20

Cereno Scientific intends to carry out a rights issue of units of approximately SEK 400 million with a focus on the global Phase IIb study EPIMODE and obtains extended loan financing of up to SEK 175 million

Cereno Scientific
Selskabsmeddelelse04.11.2026, 07.30

Cereno Scientific Publishes Interim Report for Q3 2026

Cereno Scientific
Pressemeddelelse03.11.2026, 07.30

Cereno Scientific strengthens patient engagement and EPIMODE recruitment foundations at Global PH Summit

Cereno Scientific
Pressemeddelelse02.11.2026, 09.07

Cereno Scientific Sees Strong Investigator Engagement as EPIMODE Phase IIb Trial Advances

Cereno Scientific
Selskabsmeddelelse28.10.2026, 12.23

Cereno Scientific AB (publ) publishes report from the Extraordinary General Meeting

Cereno Scientific
Pressemeddelelse16.10.2026, 08.00

Cereno Scientific to Participate at BIO-Europe 2026 as Clinical Pipeline Advances and Strategic Opportunities Expand

Cereno Scientific
Pressemeddelelse09.10.2026, 08.05

Cereno Scientific’s Nomination Committee Proposes Johan Eriksson for Election to the Board of Directors – Experienced Business Leader with Strong Shareholder Commitment

Cereno Scientific
Selskabsmeddelelse09.10.2026, 08.00

Cereno Scientific gives notice to attend Extraordinary General Meeting

Cereno Scientific
Pressemeddelelse08.10.2026, 08.30

Cereno Scientific expects up to 15 sites to be activated by year-end 2026 in the global Phase IIb EPIMODE trial; maintains Q4 2028 timeline for topline results

Cereno Scientific
Selskabsmeddelelse25.09.2026, 10.14

Cereno Scientific Reports Positive Topline Results from CS014 Phase I PK-bridging Study, Strengthening Intended Direct Path toward Phase IIb in PH-ILD

Cereno Scientific
Pressemeddelelse09.09.2026, 07.30

Cereno Scientific to engage US and international investors at H.C. Wainwright 28th Annual Global Investment Conference in New York

Cereno Scientific
Pressemeddelelse08.09.2026, 07.45

Cereno Scientific to participate at Nordic Life Science Days 2026 as clinical programs advance

Cereno Scientific
Selskabsmeddelelse26.08.2026, 08.00

Cereno Scientific Publishes Interim Report for Q2 2026

Cereno Scientific
Eksterne analyser17.08.2026, 08.53

Cereno Scientific: CS1 Phase IIb now underway - Edison

Cereno Scientific has launched the global Phase IIb study for CS1 (EPIMODE) in pulmonary arterial hypertension (PAH) with the activation of the first clinical site. We view this as a meaningful execution milestone, clearing the path to patient recruitment...

Cereno Scientific
Pressemeddelelse13.08.2026, 08.00

Cereno Scientific Activates First Clinical Site in Global Phase IIb EPIMODE Trial of CS1 in PAH, Enabling Patient Recruitment

Cereno Scientific